UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(a)
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
VALEANT
PHARMACEUTICALS
INTERNATIONAL, INC.
(Name of Issuer)
Common
Stock
(Title of Class of Securities)
91911K102
(CUSIP Number)
Steve Fraidin
Steve Milankov
Pershing
Square Capital Management, L.P.
888 Seventh Avenue, 42nd Floor
New York, New York 10019
212-813-3700
(Name,
Address and Telephone Number of Person Authorized to Receive Notices and Communications)
November 20, 2015
(Date of Event Which Requires Filing of This Statement)
If the filing
person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ¨
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other
parties to whom copies are to be sent.
* |
The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information
which would alter disclosures provided in a prior cover page. |
The information required on the remainder of this cover page
shall not be deemed to be filed for the purpose of section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the
Act (however, see the Notes).
13D
|
|
|
CUSIP No. 91911K102 |
|
Page
2
|
|
|
|
|
|
|
|
1 |
|
Name of
reporting person Pershing Square Capital Management, L.P. |
2 |
|
Check the appropriate box if a member
of a group (a) ¨ (b) ¨ |
3 |
|
SEC use only
|
4 |
|
Source of funds
OO (See Item 3) |
5 |
|
Check box if disclosure of legal
proceedings is required pursuant to Items 2(d) or 2(e) ¨ |
6 |
|
Citizenship or place of
organization Delaware |
Number of
shares beneficially
owned by each
reporting person
with |
|
7 |
|
Sole voting power
0 |
|
8 |
|
Shared voting power
34,118,551 |
|
9 |
|
Sole dispositive power
0 |
|
10 |
|
Shared dispositive power
34,118,551 |
11 |
|
Aggregate amount beneficially owned by each reporting person
34,118,551 |
12 |
|
Check box if the aggregate amount in
Row (11) excludes certain shares ¨ |
13 |
|
Percent of class represented by amount
in Row (11) 9.9%(1) |
14 |
|
Type of reporting person
IA |
(1) |
Calculated based on 343,101,797 shares of common stock, no par value, of Valeant Pharmaceuticals International, Inc. outstanding as of October 19, 2015, as reported on Valeant Pharmaceuticals International, Inc.s
quarterly report filed on Form 10-Q on October 26, 2015. |
13D
|
|
|
CUSIP No. 91911K102 |
|
Page
3
|
|
|
|
|
|
|
|
1 |
|
Name of
reporting person PS Management GP, LLC |
2 |
|
Check the appropriate box if a member
of a group (a) ¨ (b) ¨ |
3 |
|
SEC use only
|
4 |
|
Source of funds
OO (See Item 3) |
5 |
|
Check box if disclosure of legal
proceedings is required pursuant to Items 2(d) or 2(e) ¨ |
6 |
|
Citizenship or place of
organization Delaware |
Number of
shares beneficially
owned by each
reporting person
with |
|
7 |
|
Sole voting power
0 |
|
8 |
|
Shared voting power
34,118,551 |
|
9 |
|
Sole dispositive power
0 |
|
10 |
|
Shared dispositive power
34,118,551 |
11 |
|
Aggregate amount beneficially owned by each reporting person
34,118,551 |
12 |
|
Check box if the aggregate amount in
Row (11) excludes certain shares ¨ |
13 |
|
Percent of class represented by amount
in Row (11) 9.9%(2) |
14 |
|
Type of reporting person
OO |
(2) |
Calculated based on 343,101,797 shares of common stock, no par value, of Valeant Pharmaceuticals International, Inc. outstanding as of October 19, 2015, as reported on Valeant Pharmaceuticals International, Inc.s
quarterly report filed on Form 10-Q on October 26, 2015. |
13D
|
|
|
CUSIP No. 91911K102 |
|
Page
4
|
|
|
|
|
|
|
|
1 |
|
Name of
reporting person William A. Ackman |
2 |
|
Check the appropriate box if a member
of a group (see instructions)
(a) ¨ (b) ¨ |
3 |
|
SEC use only
|
4 |
|
Source of funds (see instructions)
OO (See Item 3) |
5 |
|
Check box if disclosure of legal
proceedings is required pursuant to Items 2(d) or 2(e) ¨ |
6 |
|
Citizenship or place of
organization United States |
Number of
shares beneficially
owned by each
reporting person
with |
|
7 |
|
Sole voting power
0 |
|
8 |
|
Shared voting power
34,118,551 |
|
9 |
|
Sole dispositive power
0 |
|
10 |
|
Shared dispositive power
34,118,551 |
11 |
|
Aggregate amount beneficially owned by each reporting person
34,118,551 |
12 |
|
Check box if the aggregate amount in
Row (11) excludes certain shares ¨ |
13 |
|
Percent of class represented by amount
in Row (11) 9.9%(3) |
14 |
|
Type of reporting person
IN |
(3) |
Calculated based on 343,101,797 shares of common stock, no par value, of Valeant Pharmaceuticals International, Inc. outstanding as of October 19, 2015, as reported on Valeant Pharmaceuticals International, Inc.s
quarterly report filed on Form 10-Q on October 26, 2015. |
13D
|
|
|
CUSIP No. 91911K102 |
|
Page
5
|
This Amendment No. 1 to Schedule 13D (this Amendment No. 1)
amends and supplements the statement on Schedule 13D (the Original Schedule 13D), filed on March 25, 2015 (the Original Schedule 13D, as amended and supplemented by this Amendment No. 1, the Schedule
13D), by Pershing Square Capital Management, L.P., a Delaware limited partnership (Pershing Square); PS Management GP, LLC, a Delaware limited liability company (PS Management); and William A. Ackman,
a citizen of the United States of America (together with Pershing Square and PS Management, the Reporting Persons), relating to the common stock, no par value (the Common Stock), of Valeant Pharmaceuticals
International, Inc., a corporation continued under the laws of British Columbia, Canada (the Issuer). Capitalized terms used but not defined in this amendment shall have the meanings set forth in the Schedule 13D.
Except as specifically amended by this Amendment No. 1, the Schedule 13D is unchanged.
As of November 23, 2015, the Reporting Persons beneficially own an aggregate of 34,118,551 shares of Common Stock, representing approximately
9.9% of the issued and outstanding shares of Common Stock of the Issuer. Since the Original Schedule 13D, this amount represents a beneficial ownership increase of 14,644,618 shares of Common Stock (or approximately 4.2% of the issued and
outstanding shares of Common Stock of the Issuer).
ITEM 3. |
SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION |
Item 3 of the Schedule 13D is
hereby amended and supplemented to add the following information:
The Reporting Persons purchased for the accounts of the Pershing Square
Funds a net amount of 2,144,618 shares of Common Stock and over-the-counter American-style call options referencing 12,500,000 shares of Common Stock for aggregate consideration of $475,461,812 (including commissions). In addition, the Reporting
Persons sold for the accounts of the Pershing Square Funds over-the-counter European-style call options and over-the-counter European-style put options, each call and put referencing a total of 12,500,000 shares of Common Stock and received
aggregate consideration of $168,966,200.
ITEM 4. |
PURPOSE OF TRANSACTION |
Item 4 of the Schedule 13D is hereby amended by restating
paragraphs 2 and 4, respectively, in their entirety as set forth below:
The Reporting Persons hold their stake in the Issuer for
investment purposes. Representatives of the Reporting Persons may conduct discussions from time to time with management of the Issuer, other stockholders of the Issuer and/or other relevant parties, including other companies in the Issuers
industry, in each case, relating to matters that may include the strategic plans, strategy, assets, business, financial condition, operations, and capital structure of the Issuer. The Reporting Persons may engage the Issuer, other stockholders of
the Issuer or other relevant parties in discussions that may include one or more of the other actions described in subsections (a) through (j) of Item 4 of Schedule 13D.
The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors, including the
Issuers financial position and strategic direction, the outcome of the discussions referenced above, actions taken by the Board of Directors of the Issuer, price levels of the securities of the Issuer, other investment opportunities available
to the Reporting Persons, the availability and cost of debt financing, conditions in the capital markets, financial considerations of the Reporting Persons and of the funds managed by the Reporting Persons, including, but not limited to, portfolio
weighting, composition and taxation, and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investments in the Issuer as they deem appropriate, including purchasing additional
securities of the Issuer, entering into financial instruments or other agreements which increase or decrease the Reporting Persons economic exposure with respect to their investments in the Issuer, selling some or all of the Reporting
Persons respective holdings in the Issuer, engaging in any hedging or similar transactions with respect to such holdings and/or otherwise changing their intention with respect to any and all matters referred to in Item 4 of Schedule 13D.
13D
|
|
|
CUSIP No. 91911K102 |
|
Page
6
|
ITEM 5. |
INTEREST IN SECURITIES OF THE ISSUER |
Item 5 of the Schedule 13D is hereby amended
and supplemented to add the following information:
(a), (b) The Reporting Persons beneficially own an aggregate of 34,118,551 shares
of Common Stock (the Subject Shares), which number includes: 21,618,551 shares of Common Stock, and 12,500,000 shares of Common Stock underlying over-the-counter American-style call options. The Subject Shares beneficially
owned by the Reporting Persons represent approximately 9.9% of the shares of Common Stock issued and outstanding (based upon 343,101,797 Shares stated to be outstanding as of October 19, 2015 by the Issuer in its Quarterly Report on Form 10-Q
filed with the Securities and Exchange Commission on October 26, 2015).
(c) Exhibit 99.5, which is incorporated by reference into
this Item 5 as if restated in full, describes all of the transactions in the Common Stock (or options relating to Common Stock) that were effected in the past 60 days by the Reporting Persons for the benefit of the Pershing Square Funds. Except
as set forth in Exhibit 99.5 attached hereto, no reportable transactions were effected by any Reporting Person within the last 60 days.
ITEM 6. |
CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER |
Item 6 of the Schedule 13D is hereby amended and supplemented to add the following information:
The Reporting Persons acquired American-style over-the-counter call options referencing 12,500,000 shares of the Issuer with Expiration Dates
of February 8, 2016 and January 20, 2017. In addition, the Reporting Persons sold over-the-counter European-style call options and over-the-counter European-style put options, each call and put referencing a total of 12,500,000 shares of the Issuer
with Expiration Dates of February 8, 2016 and January 20, 2017. The counterparties to such over-the-counter options are Nomura International PLC and UBS AG.
The foregoing summary of the over-the-counter options is qualified in its entirety by reference to the actual language of such contracts, the
form of which is filed as Exhibit 99.6 which is hereby incorporated by reference into this Item 6 as if restated in full.
None of
the options gives the Reporting Persons direct or indirect voting, investment or dispositive control over any securities of the Issuer or requires the counterparty thereto to acquire, hold, vote or dispose of any securities of the Issuer.
ITEM 7. |
MATERIAL TO BE FILED AS AN EXHIBIT |
Item 7 of Schedule 13D is hereby amended and
supplemented to add the following exhibits:
|
|
|
Exhibit 99.5 |
|
Trading data. |
|
|
Exhibit 99.6 |
|
Form of Share Option Contract. |
13D
|
|
|
CUSIP No. 91911K102 |
|
Page
7
|
SIGNATURES
After reasonable inquiry and to the best of each of the undersigneds knowledge and belief, each of the undersigned certify that the
information set forth in this statement is true, complete and correct.
|
|
|
|
|
|
|
|
|
Date: November 23, 2015 |
|
|
|
|
|
PERSHING SQUARE CAPITAL MANAGEMENT, L.P. |
|
|
|
|
|
|
|
|
|
|
|
By: |
|
PS Management GP, LLC, its General Partner |
|
|
|
|
|
|
|
|
|
|
|
By: |
|
/s/ William A. Ackman |
|
|
|
|
|
|
|
|
William A. Ackman |
|
|
|
|
|
|
|
|
Managing Member |
|
|
|
|
|
|
|
|
|
|
PS MANAGEMENT GP, LLC |
|
|
|
|
|
|
|
|
|
|
|
By: |
|
/s/ William A. Ackman |
|
|
|
|
|
|
|
|
William A. Ackman |
|
|
|
|
|
|
|
|
Managing Member |
|
|
|
|
|
|
|
|
|
|
/s/ William A. Ackman |
|
|
|
|
|
|
William A. Ackman |
13D
|
|
|
CUSIP No. 91911K102 |
|
Page
8
|
EXHIBIT INDEX
|
|
|
Exhibit |
|
Description |
|
|
Exhibit 99.1 |
|
Joint Filing Agreement, dated as of March 25, 2015, among Pershing Square Capital Management, L.P., PS Management GP, LLC and William A. Ackman.* |
|
|
Exhibit 99.2 |
|
Trading data.* |
|
|
Exhibit 99.3 |
|
Purchasers Letter, dated as of March 17, 2015, by Pershing Square Capital Management, L.P.* |
|
|
Exhibit 99.4 |
|
Confidentiality Agreement, by and among Pershing Square Capital Management, L.P. and Valeant Pharmaceuticals International, Inc., dated as of March 11, 2015.* |
|
|
Exhibit 99.5 |
|
Trading data. |
|
|
Exhibit 99.6 |
|
Form of Share Option Contract. |
Exhibit 99.5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Name |
|
Trade Date |
|
Buy/Sell/Exercise |
|
No. of Shares / Quantity |
|
|
Unit Cost |
|
|
Strike Price |
|
|
Trade Amount |
|
|
Security |
|
Expiration Date |
Pershing Square Holdings, Ltd. |
|
October 1, 2015 |
|
Buy |
|
|
172,748 |
|
|
$ |
178.38 |
|
|
|
N/A |
|
|
$ |
30,814,788 |
* |
|
Common Stock |
|
N/A |
Pershing Square Holdings, Ltd. |
|
October 21, 2015 |
|
Buy |
|
|
870,501 |
|
|
$ |
108.13 |
|
|
|
N/A |
|
|
$ |
94,127,099 |
|
|
Common Stock |
|
N/A |
Pershing Square Holdings, Ltd. |
|
October 21, 2015 |
|
Buy |
|
|
1,584 |
|
|
$ |
4.35 |
|
|
$ |
120.00 |
|
|
$ |
689,764 |
|
|
Listed Call Option |
|
October 23, 2015 |
Pershing Square Holdings, Ltd. |
|
November 20, 2015 |
|
Buy to Open |
|
|
3,687,444 |
|
|
$ |
23.65 |
|
|
$ |
95.00 |
|
|
$ |
87,208,051 |
|
|
OTC Call Option |
|
January 20, 2017 |
Pershing Square Holdings, Ltd. |
|
November 20, 2015 |
|
Sell to Open |
|
|
3,687,444 |
|
|
$ |
3.90 |
|
|
$ |
165.00 |
|
|
$ |
14,381,032 |
|
|
OTC Call Option |
|
January 20, 2017 |
Pershing Square Holdings, Ltd. |
|
November 20, 2015 |
|
Sell to Open |
|
|
3,687,444 |
|
|
$ |
13.00 |
|
|
$ |
60.00 |
|
|
$ |
47,936,772 |
|
|
OTC Put Option |
|
January 20, 2017 |
|
|
|
|
|
|
|
|
|
Pershing Square II, L.P. |
|
October 21, 2015 |
|
Buy |
|
|
15,656 |
|
|
$ |
108.13 |
|
|
|
N/A |
|
|
$ |
1,692,880 |
|
|
Common Stock |
|
N/A |
Pershing Square II, L.P. |
|
October 21, 2015 |
|
Buy |
|
|
27 |
|
|
$ |
4.35 |
|
|
$ |
120.00 |
|
|
$ |
11,757 |
|
|
Listed Call Option |
|
October 23, 2015 |
Pershing Square II, L.P. |
|
November 20, 2015 |
|
Buy to Open |
|
|
63,122 |
|
|
$ |
23.65 |
|
|
$ |
95.00 |
|
|
$ |
1,492,835 |
|
|
OTC Call Option |
|
January 20, 2017 |
Pershing Square II, L.P. |
|
November 20, 2015 |
|
Sell to Open |
|
|
63,122 |
|
|
$ |
3.90 |
|
|
$ |
165.00 |
|
|
$ |
246,176 |
|
|
OTC Call Option |
|
January 20, 2017 |
Pershing Square II, L.P. |
|
November 20, 2015 |
|
Sell to Open |
|
|
63,122 |
|
|
$ |
13.00 |
|
|
$ |
60.00 |
|
|
$ |
820,586 |
|
|
OTC Put Option |
|
January 20, 2017 |
Pershing Square II, L.P. |
|
November 23, 2015 |
|
Buy |
|
|
39,401 |
|
|
$ |
93.83 |
|
|
|
N/A |
|
|
$ |
3,696,815 |
|
|
Common Stock |
|
N/A |
Pershing Square II, L.P. |
|
November 23, 2015 |
|
Sell |
|
|
39,401 |
|
|
$ |
88.25 |
|
|
|
N/A |
|
|
$ |
3,477,074 |
|
|
Common Stock |
|
N/A |
Pershing Square II, L.P. |
|
November 23, 2015 |
|
Buy to Open |
|
|
82,230 |
|
|
$ |
5.57 |
|
|
$ |
100.00 |
|
|
$ |
458,350 |
|
|
OTC Call Option |
|
February 8, 2016 |
Pershing Square II, L.P. |
|
November 23, 2015 |
|
Sell to Open |
|
|
82,230 |
|
|
$ |
1.01 |
|
|
$ |
130.00 |
|
|
$ |
83,052 |
|
|
OTC Call Option |
|
February 8, 2016 |
Pershing Square II, L.P. |
|
November 23, 2015 |
|
Sell to Open |
|
|
82,230 |
|
|
$ |
3.38 |
|
|
$ |
70.00 |
|
|
$ |
277,937 |
|
|
OTC Put Option |
|
February 8, 2016 |
|
|
|
|
|
|
|
|
|
Pershing Square International, Ltd. |
|
October 1, 2015 |
|
Sell |
|
|
137,353 |
|
|
$ |
178.38 |
|
|
|
N/A |
|
|
$ |
24,501,028 |
* |
|
Common Stock |
|
N/A |
Pershing Square International, Ltd. |
|
October 21, 2015 |
|
Buy |
|
|
662,043 |
|
|
$ |
108.13 |
|
|
|
N/A |
|
|
$ |
71,586,577 |
|
|
Common Stock |
|
N/A |
Pershing Square International, Ltd. |
|
October 21, 2015 |
|
Buy |
|
|
1,208 |
|
|
$ |
4.35 |
|
|
$ |
120.00 |
|
|
$ |
526,032 |
|
|
Listed Call Option |
|
October 23, 2015 |
Pershing Square International, Ltd. |
|
November 20, 2015 |
|
Buy to Open |
|
|
2,837,875 |
|
|
$ |
23.65 |
|
|
$ |
95.00 |
|
|
$ |
67,115,744 |
|
|
OTC Call Option |
|
January 20, 2017 |
Pershing Square International, Ltd. |
|
November 20, 2015 |
|
Sell to Open |
|
|
2,837,875 |
|
|
$ |
3.90 |
|
|
$ |
165.00 |
|
|
$ |
11,067,713 |
|
|
OTC Call Option |
|
January 20, 2017 |
Pershing Square International, Ltd. |
|
November 20, 2015 |
|
Sell to Open |
|
|
2,837,875 |
|
|
$ |
13.00 |
|
|
$ |
60.00 |
|
|
$ |
36,892,375 |
|
|
OTC Put Option |
|
January 20, 2017 |
|
|
|
|
|
|
|
|
|
Pershing Square, L.P. |
|
October 1, 2015 |
|
Sell |
|
|
35,395 |
|
|
$ |
178.38 |
|
|
|
N/A |
|
|
$ |
6,313,760 |
* |
|
Common Stock |
|
N/A |
Pershing Square, L.P. |
|
October 21, 2015 |
|
Buy |
|
|
596,418 |
|
|
$ |
108.13 |
|
|
|
N/A |
|
|
$ |
64,490,559 |
|
|
Common Stock |
|
N/A |
Pershing Square, L.P. |
|
October 21, 2015 |
|
Buy |
|
|
1,081 |
|
|
$ |
4.35 |
|
|
$ |
120.00 |
|
|
$ |
470,729 |
|
|
Listed Call Option |
|
October 23, 2015 |
Pershing Square, L.P. |
|
November 20, 2015 |
|
Buy to Open |
|
|
2,531,559 |
|
|
$ |
23.65 |
|
|
$ |
95.00 |
|
|
$ |
59,871,370 |
|
|
OTC Call Option |
|
January 20, 2017 |
Pershing Square, L.P. |
|
November 20, 2015 |
|
Sell to Open |
|
|
2,531,559 |
|
|
$ |
3.90 |
|
|
$ |
165.00 |
|
|
$ |
9,873,080 |
|
|
OTC Call Option |
|
January 20, 2017 |
Pershing Square, L.P. |
|
November 20, 2015 |
|
Sell to Open |
|
|
2,531,559 |
|
|
$ |
13.00 |
|
|
$ |
60.00 |
|
|
$ |
32,910,267 |
|
|
OTC Put Option |
|
January 20, 2017 |
Pershing Square, L.P. |
|
November 23, 2015 |
|
Buy |
|
|
1,580,599 |
|
|
$ |
93.83 |
|
|
|
N/A |
|
|
$ |
148,302,131 |
|
|
Common Stock |
|
N/A |
Pershing Square, L.P. |
|
November 23, 2015 |
|
Sell |
|
|
1,580,599 |
|
|
$ |
88.25 |
|
|
|
N/A |
|
|
$ |
139,485,295 |
|
|
Common Stock |
|
N/A |
Pershing Square, L.P. |
|
November 23, 2015 |
|
Buy to Open |
|
|
3,297,770 |
|
|
$ |
5.57 |
|
|
$ |
100.00 |
|
|
$ |
18,381,770 |
|
|
OTC Call Option |
|
February 8, 2016 |
Pershing Square, L.P. |
|
November 23, 2015 |
|
Sell to Open |
|
|
3,297,770 |
|
|
$ |
1.01 |
|
|
$ |
130.00 |
|
|
$ |
3,330,748 |
|
|
OTC Call Option |
|
February 8, 2016 |
Pershing Square, L.P. |
|
November 23, 2015 |
|
Sell to Open |
|
|
3,297,770 |
|
|
$ |
3.38 |
|
|
$ |
70.00 |
|
|
$ |
11,146,463 |
|
|
OTC Put Option |
|
February 8, 2016 |
* |
This row represents trade rebalances on the first business day of the month to keep the funds trading pari-passu. |
Exhibit 99.6
|
|
|
|
|
|
|
To |
|
Equity Confirmations Team |
|
|
|
|
|
|
|
|
At |
|
PERSHING SQUARE FUNDS |
|
|
|
|
|
|
|
|
From |
|
Operations |
|
Department |
|
Derivatives |
|
|
|
|
Direct Tel |
|
|
|
Direct Fax |
|
|
|
|
Email |
|
|
|
|
|
|
Page 1 of |
|
12 |
|
Date: |
|
November [ ], 2015 |
Share Option Transaction
Dear Sirs
The purpose of this Share Option Master Confirmation
(this Master Confirmation) is to set forth the general terms and conditions of one or more Transactions (each an individual Transaction) that may be entered into between you (Counterparty) and
us (Dealer) on the Trade Date or Trade Dates specified in a Supplemental Confirmation, each substantially in the form of Schedule A hereto, confirming the specific terms and conditions of a particular Transaction (each a
Supplemental Confirmation). Each Transaction, if executed, will be a Share Option Transaction, the terms of which are specified in this Master Confirmation as supplemented by the Supplemental Confirmation (together, the
Confirmation). The entry into this Master Confirmation does not obligate either party to enter into any Transaction.
This Confirmation
constitutes a Confirmation as referred to in the Agreement specified below. This Confirmation hereby incorporates by reference the 2002 ISDA Equity Derivatives Definitions (the Equity Definitions) and the 2006 ISDA
Definitions (the Swap Definitions), each as published by the International Swaps and Derivatives Association, Inc. In the event of any inconsistency between the Equity Definitions and the Swap Definitions, the Equity Definitions
will govern. In the event of any inconsistency between either the Equity Definitions or the Swap Definitions and this Confirmation, this Confirmation will govern.
This Confirmation shall supplement, form a part of and be subject to the 2002 ISDA Master Agreement (the Agreement) entered into between
the parties on [DATE], including the Schedule thereto and the 1994 Credit Support Annex (Bilateral FormNew York Law) (the CSA) to such Schedule. In the event of any inconsistency between the provisions of the Agreement or
the CSA and the Confirmation, the Confirmation will govern for the purpose of the Transaction to which the Confirmation relates.
1. The terms of the
particular Transaction(s) to which this Master Confirmation relates are as follows:
|
|
|
General Terms: |
|
|
|
|
Trade Date: |
|
As specified in the relevant Supplemental Confirmation |
|
|
Option Style: |
|
As specified in the relevant Supplemental Confirmation |
|
|
Option Type: |
|
As specified in the relevant Supplemental Confirmation |
Page 1 of 12
|
|
|
Buyer: |
|
As specified in the relevant Supplemental Confirmation |
|
|
Seller: |
|
As specified in the relevant Supplemental Confirmation |
|
|
Shares: |
|
The common stock of Valeant Pharmaceuticals International, Inc. (the Issuer) (ticker: VRX) |
|
|
Number of Options: |
|
As specified in the relevant Supplemental Confirmation |
|
|
Option Entitlement: |
|
1 Share per Option |
|
|
Strike Price: |
|
As specified in the relevant Supplemental Confirmation |
|
|
Premium: |
|
As specified in the relevant Supplemental Confirmation |
|
|
Premium Payment Date: |
|
One (1) Settlement Cycle following the Trade Date, or if such date is not a Currency Business Day, the next following Currency Business Day. |
|
|
|
|
The Buyer shall pay the Seller the Premium on the Premium Payment Date. |
|
|
Exchange: |
|
New York Stock Exchange |
|
|
Related Exchange: |
|
Chicago Board Options Exchange |
|
|
Settlement Terms: |
|
|
|
|
Settlement Method: |
|
Physical Settlement |
|
|
Settlement Method Election: |
|
Not Applicable |
|
|
Settlement Currency: |
|
USD |
|
|
Designated Contracts: |
|
|
|
|
Designated Contract: |
|
An option contract on the Share traded on the Related Exchange with an expiry date (or the date which would have been the expiry date but for that day being a Disrupted Day or not being a Scheduled Trading Day) scheduled to occur on
the Expiration Date; provided, however, that, in the event that the Expiration Date were to occur on the third Friday of a calendar month and no option contract on the Share traded on the Related Exchange exists with an expiry date scheduled
to occur on the Expiration Date, but an option contract on the Share traded on the Related Exchange exists with an expiry date scheduled to occur on the Saturday immediately following such |
Page 2 of 12
|
|
|
|
|
|
|
Expiration Date, then such option contract shall be the Designated Contract. |
|
|
Procedures for Exercise: |
|
|
|
|
Commencement Date: |
|
The Trade Date |
|
|
Expiration Time: |
|
5:00 p.m. (local time in New York City) |
|
|
Expiration Date: |
|
As specified in the relevant Supplemental Confirmation; provided, however, that to the extent a Designated Contract exists on the Related Exchange and its expiry date is postponed, the Expiration Date shall be postponed to
the same Exchange Business Day, unless the expiry date has been postponed to a day that is not an Exchange Business Day, in which case the Expiration Date shall be postponed to the last Exchange Business Day immediately preceding the postponed
expiry date. |
|
|
Multiple Exercise: |
|
Applicable |
|
|
Minimum Number of Options: |
|
One |
|
|
Maximum Number of Options: |
|
The Number of Options remaining unexercised |
|
|
Integral Multiple: |
|
One |
|
|
Automatic Exercise: |
|
Applicable |
|
|
|
|
For purposes of Automatic Exercise, Section 3.4(b) is revised by replacing Expiration Time with Valuation Time |
|
|
In-the-Money: |
|
In the case of a Call: the Reference Price is greater than the Strike Price |
|
|
|
|
In the case of a Put: the Reference Price is less than the Strike Price |
|
|
Reference Price: |
|
Means the Relevant Price of the Share as of the Valuation Time on the Expiration Date |
|
|
Sellers Telephone Number and/or Facsimile Number and Contact Details for the purpose of Giving Notice: |
|
To be advised |
|
|
Share Adjustments: |
|
|
|
|
Method of Adjustment: |
|
Options Exchange Adjustment |
|
|
Options Exchange: |
|
The Related Exchange |
|
|
Extraordinary Events: |
|
|
Page 3 of 12
|
|
|
|
|
Consequences of Merger Events: |
|
|
|
|
Share-for-Share: |
|
Options Exchange Adjustment |
|
|
Share-for-Other: |
|
Options Exchange Adjustment |
|
|
Share-for-Combined: |
|
Options Exchange Adjustment |
|
|
Tender Offer: |
|
Applicable; provided, however, that so long as there has not occurred a Designated Contract Disruption, then Section 12.1(d) of the Equity Definitions shall be amended to read, in its entirety, as follows: |
|
|
|
|
Tender Offer means any tender offer that, per the rules and/or by-laws of the Options Exchange, results in an adjustment to option contracts of the Issuer. |
|
|
Consequences of Tender Offer: |
|
|
|
|
Share-for-Share: |
|
Options Exchange Adjustment |
|
|
Share-for-Other: |
|
Options Exchange Adjustment |
|
|
Share-for-Combined: |
|
Options Exchange Adjustment |
|
|
Composition of Combined |
|
|
Consideration: |
|
Section 12.5 of the Equity Definitions shall not apply; provided, however, that if a Designated Contract Disruption has occurred, then Composition of Combined Consideration shall be Not Applicable |
|
|
Nationalization, Insolvency or |
|
|
Delisting: |
|
Notwithstanding Section 12.6(c) of the Equity Definitions, (i) if a Designated Contract Disruption has not occurred and is not continuing, Options Exchange Adjustment shall be the consequence of Nationalization, Insolvency or
Delisting as if Nationalization, Insolvency or Delisting were a Merger Event for the purpose of this Transaction; and (ii) if a Designated Contract Disruption has occurred and the Transaction has not been terminated (if applicable), then
(irrespective of whether Designated Contract Disruption is Applicable or Not Applicable) the consequences of Nationalization, Insolvency, or Delisting shall be Cancellation and Payment (Calculation Agent Determination); provided, further that
in addition to the provisions of Section 12.6(a)(iii) of the Equity Definition, it shall also constitute a Delisting if the Exchange is located in the United States and the Shares are not immediately re-listed, re-traded or re-quoted on any of the
New York Stock Exchange, the NASDAQ Global Select Market or the NASDAQ Global Market (or their respective successors); if the |
Page 4 of 12
|
|
|
|
|
|
|
Shares are immediately re-listed, re-traded or re-quoted on any exchange or quotation system, such exchange or quotation system shall be deemed to be the Exchange. |
|
|
Additional Disruption Events: |
|
|
|
|
Designated Contract Disruption: |
|
Not Applicable |
|
|
|
|
Designated Contract Disruption means at any time prior to the Expiration Date, an official announcement by the applicable Related Exchange that trading on the Designated Contract shall be permanently discontinued.
For the avoidance of doubt, it shall not be a Designated Contract Disruption if the Designated Contract is permitted to settle on the Related Exchange. |
|
|
|
|
If Designated Contract Disruption is Applicable, then upon or following the occurrence of such an event, either party may elect, while the Designated Contract Disruption is continuing, to terminate this Transaction upon at least one
Scheduled Trading Days notice, specifying the date of such termination, which may be no earlier than the effective date of the Designated Contracts permanent discontinuance. The Determining Party shall determine the Cancellation Amount
payable by one party to the other, in accordance with Section 12.8 of the Equity Definitions. |
|
|
|
|
If Designated Contract Disruption is Not Applicable, then upon or following the occurrence of a Designated Contract Disruption, Options Exchange Adjustment shall apply. |
|
|
Change in Law: |
|
Not Applicable |
|
|
Failure to Deliver: |
|
Applicable |
|
|
Insolvency Filing: |
|
Not Applicable; provided that Insolvency Filing shall be treated as Nationalization, Insolvency or Delisting under this Transaction for purposes of determining the consequences (if any) of such an event occurring |
|
|
Determining Party: |
|
Dealer and Counterparty |
|
Additional Representations, Agreements and Acknowledgments: |
|
|
Non-Reliance: |
|
Applicable |
|
|
Agreements and Acknowledgments |
|
|
Regarding Hedging Activities: |
|
Applicable |
|
|
Additional Acknowledgments: |
|
Applicable |
Page 5 of 12
|
|
|
Eligible Contract Participant: |
|
Each party represents to the other party that it is an eligible contract participant as defined in the U.S. Commodity Exchange Act (as amended) |
2. Calculation Agent: Dealer, provided however that Counterparty may challenge any determination or calculation
made by the Calculation Agent within two Business Days following receipt by Counterparty of such determination or calculation, subject to providing in reasonable details the material reasons for the dispute and suggesting an alternative calculation
or determination. If the parties are unable to agree on such determination or calculation within one Business Day, (i) the relevant party shall pay the amount, if any, which is not in dispute and (ii) a mutually acceptable third party will
be appointed by the parties within two Business Days following such challenge to act as Substitute Calculation Agent and make the relevant determination or calculation. If the parties are unable within two Business Days to agree on, or to appoint,
such third party, then each party will, within two Business Days select a leading, independent dealer in instruments of the type covered by this Master Confirmation and such dealers shall agree on a third party who shall also be a leading,
independent dealer in instruments of the type covered by this Master Confirmation to act as Substitute Calculation Agent. Subject to the above, all determinations and calculations by the Substitute Calculation Agent will be binding and conclusive in
the absence of manifest error. The costs, fees and expenses (if any) relating to the appointment of a third party shall be borne equally by both parties.
3. Address for Notices:
Notice to
Dealer:
with a copy to:
Notice to Counterparty:
Steve
Milankov
c/o Pershing Square Capital Management, L.P.
888 Seventh Avenue, 42nd Floor
New York, NY 10019
with a copy
to:
Ramy Saad
c/o Pershing
Square Capital Management, L.P.
888 Seventh Avenue, 42nd Floor
New York, NY 10019
4. Account Details:
|
|
|
|
|
Account details for Dealer: |
|
To be advised. |
|
|
Account details for Counterparty: |
|
To be advised. |
Page 6 of 12
5. Other Provisions:
(a) |
Independent Amount. The Independent Amount will be set forth in a relevant Supplemental Confirmation and is payable by the Counterparty to the Dealer in accordance with the CSA. |
(b) |
Additional Representations and Warranties of Counterparty. |
Counterparty hereby
represents and warrants to Dealer as of the date hereof, and as of each date on which a Transaction is executed hereunder, and covenants with Dealer, that:
|
(i) |
Counterparty represents that the execution of any Transaction by it is not in violation of Section 10(b) of the 1934 Act. In addition, if the Counterparty seeks to amend any Transaction, the Counterparty will be
deemed to represent that the Counterparty is not in violation of Section 10(b) of the 1934 Act. |
|
(ii) |
Counterparty is aware of its obligations under the United States Federal securities laws in respect of the Shares, including without limitation under Sections 9 and 10(b) of the 1934 Act, as amended, and the rules and
regulations thereunder, and during the term of the Transaction will not take any action that does not comply with those obligations. |
|
(iii) |
Without limiting the generality of Section 3(a)(iii) of the Agreement, Counterparty is and, after giving effect to the Transaction, will be in compliance with any reporting obligations under Section 16,
Section 13(d) and Section 13(g) of the 1934 Act it has with respect to the Shares. |
|
(iv) |
Counterparty is not and, after giving effect to the transactions contemplated hereby, will not be required to register as an investment company under, and as such term is defined in, the Investment Company
Act of 1940, as amended. |
|
(v) |
Counterparty is, and shall be as of the date of any payment or delivery by Counterparty hereunder, solvent and able to pay its debts as they come due, with assets having a fair value greater than liabilities and with
capital sufficient to carry on the businesses in which it engages. |
|
(vi) |
Without limiting the generality of Section 13.1 of the Equity Definitions, Counterparty acknowledges that (A) Dealer is not making any representations or warranties or giving any advice with respect to the
legal, regulatory, accounting or tax treatment of the Transaction, and Counterparty has consulted with its own legal, regulatory, accounting and tax advisors with respect to the Transaction, and (B) none of Dealer and its affiliates has acted
or will act as Counterpartys fiduciary in any way, or has any fiduciary duties to Counterparty; and Counterparty is not relying, has not relied and will not rely upon any communication (written or oral) of Dealer or any of its affiliates.
Counterparty has made or will make its own independent decision to enter into the Transaction based upon its own judgment and upon advice of such advisors as Counterparty deems necessary. |
|
(vii) |
Counterparty is not an affiliate (as defined in Rule 144) of the Issuer. It shall promptly notify the other party if it has become an affiliate of the Issuer. |
|
(viii) |
Counterparty is aware of its obligations under Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in respect of the Shares, and to the extent that physical settlement would apply to an Option Transaction,
any required filings and any applicable waiting periods under such Act relating to the transactions contemplated hereby, have been made or have expired or been terminated, as applicable. |
Page 7 of 12
Buyer represents and warrants to Seller that (i) it is an
accredited investor as that term is defined in Regulation D as promulgated under the Securities Act of 1933, as amended (the Securities Act), (ii) it is entering into the Transaction for its own account without a
view to the distribution or resale thereof and (iii) it understands that the assignment, transfer or other disposition of the Transaction has not been and will not be registered under the Securities Act.
(d) |
Matters relating to Dealer and the Agent. |
|
(i) |
Dealer is not registered as a broker or dealer under the Exchange Act. [BROKER] (Agent) has acted solely as agent for Dealer and Counterparty to the extent required by law in connection with the Transaction
and has no obligations, by way of issuance, endorsement, guarantee or otherwise, with respect to the performance of either party under the Transaction. The parties agree to proceed solely against each other, and not against Agent, in seeking
enforcement of their rights and obligations with respect to the Transaction, including their rights and obligations with respect to payment of funds and delivery of securities. |
|
(ii) |
Agent may have been paid a fee by Dealer in connection with the Transaction. Further details will be furnished upon written request. |
|
(iii) |
The time of the Transaction will be furnished by Agent upon written request. |
(e) |
Acknowledgments Regarding Hedging. |
Counterparty acknowledges, and with respect to
clause (vi), Counterparty and Dealer acknowledge that:
|
(i) |
during the term of the Transaction, Dealer and its affiliates may buy or sell Shares or other securities or buy or sell options or futures contracts or enter into swaps or other derivative securities in order to
establish, adjust or unwind its hedge position with respect to the Transaction; |
|
(ii) |
Dealer and its affiliates may also be active in the market for the Shares and derivatives linked to the Shares other than in connection with hedging activities in relation to the Transaction, including acting as agent
or as principal and for its own account or on behalf of customers; |
|
(iii) |
Dealer shall make its own determination as to whether, when or in what manner any hedging or market activities in the Shares shall be conducted and shall do so in a manner that it deems appropriate to hedge its price
and market risk with respect to the Transaction; |
|
(iv) |
any market activities of Dealer and its affiliates with respect to the Shares may affect the market price and volatility of the Shares, each in a manner that may be adverse to Counterparty; |
|
(v) |
the Transaction is a derivatives transaction in which it has purchased from or sold to (as applicable) Dealer an option; Dealer may purchase or sell Shares for its own account at an average price that may be greater
than, or less than, the price paid to Counterparty under the terms of the Transaction; and |
|
(vi) |
without limiting the generality of the foregoing, any initial price of the Transaction is not the execution price of any initial hedge of the Dealer
(if the Dealer chooses to hedge any risk with respect to the Transaction), taking into |
Page 8 of 12
|
account any applicable fees or commissions, but rather is an initial price that is at risk to the Dealer (as determined by the Dealer in its sole discretion). |
Counterparty and Dealer understand that there may exist one or more
confidentiality agreement(s) between Counterparty and Dealer. With respect to any rights or obligations thereunder to maintain the confidential nature of confidential information (as defined therein), the parties agree to continue to maintain the
confidential nature of confidential information.
Page 9 of 12
Please confirm your agreement to be bound by the terms of the foregoing by executing a copy of this Master
Confirmation and returning it to us.
Yours faithfully,
For and on behalf of
DEALER
Confirmed as of the date
first
above written:
For and on behalf of
PERSHING SQUARE
FUNDS
By: Pershing Square Capital Management, L.P., its Investment Manager
By: PS Management GP, LLC, its General Partner
|
|
|
By: |
|
|
Name: |
|
William A. Ackman, |
Title: |
|
Managing Member |
Page 10 of 12
SHARE OPTION SUPPLEMENTAL CONFIRMATION
|
|
|
To: |
|
Pershing Square Funds |
|
|
Attention: |
|
c/o Pershing Square Capital Management, L.P. |
|
|
888 Seventh Avenue, 42nd Floor |
|
|
New York, NY 10019 |
Date:
Dear Sir/Madam:
The purpose of this Share Option Supplemental Confirmation (this Supplemental Confirmation) is to confirm the specific terms and conditions
of the individual Transaction(s) (each a Transaction) entered into between you (Counterparty) and us (Dealer) on the Trade Date specified below. This Supplemental Confirmation supplements the
Share Option Master Confirmation between you and us dated November [ ], 2015.
The terms of the particular individual
Transaction(s) to which this Supplemental Confirmation relates are as follows:
Transaction 1:
Trade Date:
Option Style:
Option Type:
Buyer:
Seller:
Number of Options:
Strike Price:
Premium:
Independent Amount:
Transaction 2:
[ ]
Transaction 3:
[ ]
Page 11 of 12
Please confirm your agreement to be bound by the terms of the foregoing by executing a copy of this Supplemental
Confirmation and returning it to us.
|
|
|
Yours faithfully, |
|
DEALER |
|
|
By: |
|
|
Name: |
|
|
Title: |
|
|
Confirmed as of the date first written above:
PERSHING SQUARE FUNDS
By: Pershing Square Capital
Management,
L.P., its Investment Manager
By: PS Management
GP, LLC, its General
Partner
|
|
|
By: |
|
|
Name: |
|
William A. Ackman |
Title: |
|
Managing Member |
Page 12 of 12
Valeant Pharma (NYSE:VRX)
Historical Stock Chart
From Apr 2024 to May 2024
Valeant Pharma (NYSE:VRX)
Historical Stock Chart
From May 2023 to May 2024